Insider Trading April 6, 2026

Lands’ End Director Disposes of 752 Shares; Stock Trades Far Below Sale Price

Director Gordon Hartogensis sold $33,840 of Lands’ End stock as the company reports mixed fourth-quarter results and launches a $100 million buyback plan

By Sofia Navarro LE
Lands’ End Director Disposes of 752 Shares; Stock Trades Far Below Sale Price
LE

Director Gordon Hartogensis sold 752 shares of Lands’ End common stock on April 1, 2026, for $45.00 per share, totaling $33,840. After the sale he directly holds 9,142 shares. The company’s shares have since fallen to $10.90, a year-to-date decline of about 21%. InvestingPro places a fair value on the stock at $14.90. Lands’ End reported fiscal 2025 fourth-quarter EPS of $0.76 on revenue of $462.4 million, each missing analyst forecasts, though total revenue rose 5% year-over-year. The Board authorized a share repurchase program of up to $100 million through March 31, 2029.

Key Points

  • Director Gordon Hartogensis sold 752 Lands’ End shares on April 1, 2026, for $33,840 total; he now directly owns 9,142 shares.
  • Lands’ End’s stock is trading at $10.90, down roughly 21% year-to-date, while InvestingPro values the stock at $14.90; market cap is $337 million with a P/E of 60.91.
  • The company missed fourth-quarter fiscal 2025 EPS and revenue forecasts but recorded a 5% increase in total revenue year-over-year and secured Board approval for a $100 million buyback program through March 31, 2029.

Gordon Hartogensis, a director at Lands’ End, Inc. (NASDAQ: LE), disclosed a sale of 752 shares of the company’s common stock on April 1, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at $45.00 apiece for an aggregate proceeds amounting to $33,840. After completing the transaction, Hartogensis retained direct ownership of 9,142 shares.


Market movement since the sale has been material. Lands’ End shares are currently trading at $10.90, representing roughly a 21% year-to-date decline from prior levels. Independently, InvestingPro’s analysis places the stock below its calculated intrinsic level, assigning a Fair Value of $14.90. The company carries a market capitalization of $337 million and is trading at a price-to-earnings ratio of 60.91.


Recent company results provide context for investor reactions. In its fourth quarter for fiscal year 2025, Lands’ End reported earnings per share of $0.76, which fell short of an expected $0.79. Revenue for the quarter came in at $462.4 million, missing the anticipated $472.24 million, although the company did record a 5% increase in total revenue compared with the same period in the prior year.

Alongside the quarterly report, Lands’ End announced that its Board of Directors has authorized a share repurchase program of up to $100 million of common stock to be available through March 31, 2029. The company said it intends to carry out repurchases via open market transactions, privately negotiated transactions, or by other means permitted under federal securities laws.


Summary of the transaction and company metrics:

  • Insider sale: 752 shares sold on April 1, 2026, at $45.00 per share, for total proceeds of $33,840.
  • Post-transaction insider holding: 9,142 shares directly owned by Hartogensis.
  • Current trading price: $10.90; year-to-date loss of approximately 21%.
  • Valuation snapshot: InvestingPro Fair Value $14.90; market cap $337 million; P/E 60.91.
  • Latest quarter: EPS $0.76 vs. forecast $0.79; revenue $462.4 million vs. expected $472.24 million; total revenue increased 5% year-over-year.
  • Buyback authorization: Up to $100 million through March 31, 2029, to be executed in accordance with federal securities laws.

This disclosure reflects the filing details and the company-reported financial results. The reported insider sale, current market price, valuation estimate, quarterly results and share repurchase authorization are presented as reported; no additional interpretation beyond these reported data points is provided here.

Risks

  • Quarterly results missed analyst forecasts on both EPS and revenue, which may continue to exert downward pressure on the stock; this affects equity investors and retail sector valuations.
  • The share repurchase program is subject to execution risk and legal constraints under federal securities laws, which could limit the pace or scale of buybacks; this impacts capital allocation outcomes for shareholders.
  • The significant decline in the share price since the insider sale suggests heightened market volatility and potential liquidity concerns for holders of Lands’ End stock; this bears on market participants in the consumer retail sector.

More from Insider Trading

Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026 Kinder Morgan Vice President Disposes of $203K in Class P Shares Apr 6, 2026 RA Capital Disposes $14.5M of Vor Biopharma Stock Across Early April Trades Apr 6, 2026 Magnetar Financial Disposes of 23,088 Wheeler Real Estate Shares for About $21.5k Apr 6, 2026 Lipocine CEO Mahesh Patel Buys $50,749 of Stock as Company Reports Phase 3 Setback Apr 6, 2026